EarlySight and PulseSight Therapeutics collaborate to add Cellularis® 2 Retinal Imaging to PST-611 Phase 2 Study Posted on October 9, 2026October 12, 2026 by edgover
PulseSight’s PST-611 Shows 35-52% Slowing of Retinal Cell Loss Biomarkers in Phase I Geographic Atrophy Trial Posted on October 8, 2026October 19, 2026 by edgover
PulseSight Reports Favorable Safety and Early Efficacy Signals for PST-611 in Geographic Atrophy Posted on October 7, 2026October 20, 2026 by edgover
RetinAI and PulseSight Therapeutics Expand Collaboration to Support Advancement of PST-611 Gene Therapy Program for Geographic Atrophy into Phase 2a Posted on October 2, 2026October 12, 2026 by edgover
Judith Greciet on Targeting Iron Dysregulation: PulseSight’s Next-Generation Approach to Geographic Atrophy Posted on August 7, 2026August 7, 2026 by edgover
PulseSight Therapeutics Reports P-I (PST-611-CT1) Trial Data on PST-611 in Dry AMD/Geographic Atrophy Posted on May 11, 2026June 22, 2026 by edgover
PulseSight completes Phase 1 dosing of gene therapy candidate PST-611 in dry AMD and geographic atrophy Posted on May 5, 2026June 22, 2026 by edgover
PulseSight Completes Enrollment in Gene Therapy Trial Posted on January 22, 2026January 23, 2026 by edgover